10O Efficacy according to PD-L1 status in the BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) randomised phase III trial of first-line atezolizumab (atezo), chemotherapy (CT) and bevacizumab (bev) for metastatic, persistent or recurrent cervical cancer (R/M CC)
Year: 2025
Type: article
Abstract: Adding atezo to first-line CT + bev for R/M CC significantly improved the dual primary endpoints of progression-free survival (PFS) and overall survival (OS) in the open-label randomised phase III BEATcc trial (NCT03556839). Median OS with atezo + CT + bev exceeded 2.5 years. The effect of atezo in R/M CC according to PD-L1 status is unknown.
Source: ESMO Open
Institutions: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Centre Hospitalier Universitaire de Besançon, Hospital Universitario Virgen de la Arrixaca, Spanish Ovarian Cancer Research Group, Solti, Vall d'Hebron Institute of Oncology, Shizuoka Cancer Center, Oslo University Hospital, University of Oslo, University Medical Center Hamburg-Eppendorf, Willis-Knighton Cancer Center, Louisiana State University Health Sciences Center Shreveport, Ospedale Sant'Anna, Hospices Civils de Lyon, Hôpital Lyon Sud, Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red, Hospital Clínico Universitario Virgen de la Victoria, Centro de Investigación Biomédica en Red de Cáncer, Instituto de Investigación Biomédica de Málaga, Saitama International Medical Center, Saitama Medical University, Hospital Universitario Reina Sofía, Institut de Cancérologie de l'Ouest, L’Institut du Cancer Courlancy Reims, Agostino Gemelli University Polyclinic, Istituti di Ricovero e Cura a Carattere Scientifico, Karolinska University Hospital, Karolinska Institutet
Language: English
Subfield: Obstetrics and Gynecology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,910
OpenAlex ID: W4411643446